Spectral MD Holdings, Ltd
("Spectral MD" or the "Company")
Result of AGM
LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI and optical technology for faster and more accurate treatment decisions in wound care, announces that at the AGM held earlier today, all resolutions were duly passed.
Full details of the voting results, below:
Resolution |
Total votes for | % of votes cast | Total votes against | % of votes cast |
Votes withheld |
(1) To elect Richard Cotton and Martin Mellish (the "Director Nominees") as Class I directors to serve on the board of directors until the 2025 Annual Meeting of Stockholders and until each of their respective successors have been duly elected and qualified | 96,621,896 | 100.0% | -- | -- | -- |
(2) To approve the 2022 Long-Term Incentive Plan | 65,099,790 | 67.4% | 5,975,420 | 6.2% | 25,546,686 |
For further information please contact:
Spectral MD Holdings, Ltd. | investors.spectralmd.com | |
Wensheng Fan, Chief Executive Officer | via Walbrook PR | |
Nils Windler, Chief Financial Officer |
| |
|
| |
SP Angel Corporate Finance LLP (NOMAD and Joint Broker) | Tel: +44 (0)20 3470 0470 | |
Stuart Gledhill/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Sales & Broking)
Stifel Nicolaus Europe Limited (Joint Broker) Charles Hoare / Ben Maddison / Nick Harland / Will Palmer-Brown |
Tel: +44 (0)20 7710 7600 | |
|
| |
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com | |
Paul McManus / Louis Ashe-Jepson Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393 +44 (0)7407 804 654 | |
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.
www.spectralmd.com
info@spectralmd.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.